We are proud to announce that the Voice of the Patient Report from the Externally-Led Patient-Focused Drug Development (EL-PFDD) Meeting on Angelman Syndrome has been officially submitted to the U.S. Food and Drug Administration (FDA).
Hosted by ASF and FAST, this meeting brought together hundreds of families, caregivers, researchers, clinicians, FDA representatives, and industry partners to spotlight the urgent, unmet needs of people living with Angelman syndrome. This powerful report captures the lived experiences of individuals with Angelman syndrome and their families.
This milestone reflects the strength of the Angelman syndrome community—a community that continues to drive science forward and ensure decision makers have the knowledge needed to bring meaningful treatments to life.